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INTRODUCTION
Multiple organ failure (MOF) is com-
mon (30%) in the severely injured popu-
lation and, if not fatal, results in serious
outcomes such as prolonged critical care
and hospital stays, and poor long-term
quality of life (1). Development of MOF
occurs early (within 2 d of admission)
and correlates with an increase in noso-
comial infections and, if it persists, mor-
tality (2). This figure rises rapidly as the
degree of blood loss and shock intensi-
fies. Patients requiring at least four units
of red cell transfusions have longer criti-
cal care (9 versus 5 d) and hospital stays
(25 versus 15 d). They also have a higher
mortality rate (35% versus 6%). Even
modest improvements in these figures
would significantly improve patient ex-
perience and quality of life and reduce
the costs of healthcare. Currently there
are no specific treatments for organ fail-
ure. Resuscitation after severe hemor-
rhage improves tissue perfusion but
does not alleviate reperfusion injury nor
dampen the systemic inflammatory re-
sponse, both of which importantly con-
tribute to the development of organ
 injury/dysfunction and ultimately MOF
(3). A therapeutic agent that reduces the
incidence and severity of multiple organ
failure could have a major global impact
on patient outcomes and resource 
utilization.
Nuclear factor-kappa B (NF-κB) is the
main transcription factor that regulates
the expression of genes involved in the
inflammatory response. Functionally ac-
tive NF-κB is a heterodimer, which is nor-
mally sequestered in an inactive cytoplas-
mic complex by binding to the inhibitory
protein IκBα (4). External stimuli such as
inflammatory cytokines, bacterial
lipopolysaccharides and reactive oxygen
species (ROS) activate the IκB kinase
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(IKK) complex, which in turn causes the
rapid phosphorylation of IκBα at Ser32/36
(5). Phosphorylated IκBα becomes ubiq-
uitinated and is subsequently degraded
by proteasomes, releasing NF-κB, which
is free to translocate to the nucleus to reg-
ulate the transcription of a wide variety
of genes that encode inflammatory pro-
teins, including iNOS and the proinflam-
matory cytokines tumor necrosis factor-α
(TNF-α) and interleukin-6 (IL-6), to name
but a few (6,7).
There is now growing evidence that
inhibition of the activation of NF-κB may
reduce organ injury and dysfunction in
septic and hemorrhagic shock (HS)
(8–11). The inhibition of IKK complex by
IKK16 and the consequent prevention of
the activation of NF-κB reduce the car-
diac dysfunction, liver injury and renal
dysfunction caused by sepsis (12) and
ventilation-induced lung injury (13).
There is indirect evidence that agents
that prevent the activation of NF-κB (for
example, calpain inhibitor I) are also of
benefit in HS (14). Other examples in-
clude ciglitazone (a peroxisome prolifer-
ator-activated receptor [PPAR]-γ ligand)
and eritoran (a toll-like receptor 4 [TLR4]
antagonist), which attenuate organ dam-
age in HS through the indirect inhibition
of NF-κB (8,10). However, the effects of
the inhibition of IKK in HS have yet to
be investigated. Therefore, the aim of the
present study was to investigate the ef-
fects of IKK16, a potent inhibitor of the
IKK complex, on the multiple organ in-
jury and dysfunction induced by HS in
the rat. Having found that IKK16 re-
duced the organ injury/dysfunction as-
sociated with HS in the rat, we then in-
vestigated the mechanism of action
(signaling) of the observed effects of
IKK16 in organs (ex vivo) and in cultured
cells in vitro.
MATERIALS AND METHODS
Animal Welfare and Ethics Statements
The animal protocols used in this
study were approved by the Animal Wel-
fare Ethics Review Board (AWERB) of
Queen Mary University of London (PPL:
70/7348) in accordance with the deriva-
tives of Home Office guidance on Opera-
tion of Animals (Scientific Procedures
Act 1986) published by Her Majesty’s
Stationery Office and the Guide for the
Care and Use of Laboratory Animals of
the National Research Council.
Hemorrhagic Shock Model and
Organ Injury Assessment
A timeline of the HS protocol is pro-
vided in Figure 1. This study was carried
out on 39 male Wistar rats (Charles River
Ltd.) weighing 230 to 280 g and receiving
a standard diet and water ad libitum. All
data from rats that had died during the
experiment were recorded but were ex-
cluded from the data analysis. Thus, the
n numbers provided in figures and text
represent those animals that survived the
entire experimental protocol. The animals
were housed in a temperature- controlled
environment with a 12-h light–dark cycle.
Hemorrhagic shock was performed as
previously described (15). Rats were
anaesthetized with sodium thiopentone
(120 mg/kg intraperitoneal [IP] main-
tained using 10 mg/kg intravenous [i.v.])
and cannulation with polyethylene
catheters of the trachea, bladder (to col-
lect urine), jugular vein (to administer
compounds and blood), left femoral ar-
tery (for recording of mean arterial pres-
sure [MAP]) and right carotid artery (for
blood withdrawn) was performed. Body
temperature was monitored by a rectal
thermometer and maintained at 37°C ±
0.5°C by means of a homoeothermic blan-
ket system (Harvard Apparatus). Briefly,
blood was withdrawn to achieve a fall in
MAP to 30 ± 2 mmHg within 5 min,
which was recorded with a pressure
transducer coupled to a PowerLab 8/30
(AD Instruments Pty Ltd.). The average ±
standard deviation (SD) volumes of
blood withdrawn were 9.4 ± 0.74 and
9.61 ± 0.99 mL for the HS and HS +
IKK16 groups, respectively (p > 0.05).
MAP was maintained at 30 ± 2 mmHg
for a period of 90 min either by further
withdrawal of blood during the compen-
sation phase or administration of the
shed blood during the decompensation
phase. At 90 min after initiation of hem-
orrhage or when 25% of the shed blood
had to be reinjected to sustain MAP at
30 mmHg, resuscitation was performed
with the remaining shed blood mixed
with 100 IU/mL heparinized saline plus
then the same volume of blood spent
during decompensation of Ringer lactate
over a period of 5 min. As different vol-
umes of blood were withdrawn to reach
an MAP of 30 ± 2 mmHg, the average ±
SD values for the rate of resuscitation
were 1.4 ± 0.07 and 1.58 ± 0.24 mL/min
for the HS + vehicle and HS + IKK16
groups, respectively (p > 0.05). One hour
after resuscitation an infusion of Ringer
lactate (1.5 mL/kg/h; i.v.) was started as
fluid replacement and it was maintained
throughout the experiment for a total of 
4 h. The last 3-h urine was obtained for the
estimation of creatinine clearance. Then,
blood samples were collected via the
carotid artery for measurement of lactate
(Accutrend Plus Meter, Roche Diagnos-
tics), blood cell counts (IDEXX ProCyte
Dx® Hematology Analyzer; IDEXX Labo-
ratories Ltd.) and organ injury parame-
ters. The heart was removed to terminate
the experiment. Blood samples were cen-
trifuged to separate serum from which
creatinine, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), li-
pase, amylase and creatine kinase (CK)
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Figure 1. Timeline of the experimental protocol.
were measured within 24 h (IDEXX Labo-
ratories Ltd). In addition, lung, kidney
and liver samples were taken and stored
at –80°C for further analysis. Sham-oper-
ated rats were used as control and under-
went identical surgical procedures but
without hemorrhage or resuscitation.
Experimental Design
Rats were randomly allocated into the
following groups: Sham + Vehicle (n = 9),
Sham + IKK16 (n = 8); HS + Vehicle (n =
11) and HS + IKK16 (n = 11). Rats were ad-
ministered i.v. vehicle (10% dimethyl sul-
foxide [DMSO]) or IKK16 (1 mg/mL/kg)
upon resuscitation. The dose of IKK16 was
chosen based on our previous experience
(12).
Lung Myeloperoxidase Activity
The activity of myeloperoxidase was
determined as an indicator of neutrophil
accumulation into the lungs. Samples
were homogenized in a 5 mmol/L phos-
phate buffer and centrifuged for 30 min
at 13,000g at 4°C. The supernatant was
allowed to react with a solution of 
o-dianisidine (0.167 mg/mL) and H2O2
(0.1 mmol/L) in 50 mmol/L phosphate
buffer. The rate of change in absorbance
was measured spectrophotometrically at
460 nm. Myeloperoxidase activity was
defined as the quantity of enzyme de-
grading 1 μmol of peroxide/min at 37°C
and was expressed in milliunits/g of wet
tissue.
Lung N-Acetyl-β-D-Glucosaminidase
Determination
Lung N-acetyl-β-D-glucosaminidase
(NAG) was measured as an index of
macrophage influx. Lung samples were
homogenized in Tris-HCl buffer contain-
ing NP-40 (1%), sodium deoxycholate
(0,25%), ethylene glycol tetraacetic acid
(EGTA; 1 mmoL/L) and protease in-
hibitor cocktail (1 μL/mL; P-8340; Sigma-
Aldrich). The homogenates were cen-
trifuged at 10,000g at 4°C for 10 min and
the supernatants were stored at –80°C.
The protein content was determined in
each sample using a BCA protein assay
(Thermo-Fisher Scientific, Inc.). N-acetyl-
β-D-glucosaminidase (NAG) was deter-
mined on the lung homogenates using a
commercial immunoassay kit (Elab-
science Biotechnology Co., Ltd.) accord-
ing to the protocol provided by the man-
ufacturer. The results were expressed as
ng/mg of protein.
Immunohistochemistry
Kidney, liver and lung samples were
obtained from rats after the end of the ex-
periment and were fixed in formalin for
48 h. Then, tissues were transferred to
70% ethanol solution, embedded in paraf-
fin and processed to obtain 4-μm sections.
After deparaffinization, the antigens were
retrieved by incubation with 1× citrate
buffer (pH 6.0, antigen retriever, Sigma-
Aldrich) for 15 min at microwave (700 watts).
After cooling, sections were incubated
with 0.03% H2O2 for inactivation of en-
dogenous peroxidase. Nonspecific ad-
sorption was minimized by incubating
the sections with 10% goat serum for 
15 min. The slides were then incubated
with rabbit anti-myeloperoxidase anti-
body (1:25, catalog no. ab9535; Abcam) or
anti-CD68 antibody ED1 (1:400; catalog
no. MCA341R; AbD Serotec) for 1 h at
37°C. After washing with phosphate-
bufferd saline (PBS), slides were incu-
bated for 30 min with labeled polymer-
HRP antibody, washed and incubated
with DAB (3,3′-diaminobenzidine) chro-
mogen solution (EnVision+ System-HRP
(DAB); K4010; Dako). A negative control
was performed through the omission of
primary antibody (data not shown). The
reaction was stopped by immersing slides
in water. Counterstaining was performed
with Harris hematoxylin. Images were ac-
quired using a NanoZoomer Digital
Pathology Scanner (Hamamatsu Photon-
ics K.K.) and analyzed using the NDP
Viewer software. The numbers of CD68-
and myeloperoxidase (MPO)-positive
cells were counted in 10 randomly se-
lected fields (400×) in a double-blinded
manner.
Western Blotting
Briefly, kidney and liver samples were
homogenized in buffer and centrifuged at
1,300g for 5 min at 4°C. To obtain the cy-
tosolic fraction, supernatants were cen-
trifuged at 16,000g at 4°C for 40 min. The
pelleted nuclei were resuspended in ex-
traction buffer and centrifuged at 16,000g
for 20 min at 4°C. Protein content was de-
termined on both nuclear and cytosolic
extracts using a bicinchoninic acid pro-
tein assay (Thermo-Fisher Scientific Inc.).
Proteins were separated by 8% sodium
dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred
to a polyvinyldenediflouoride (PVDF)
membrane, which was incubated with a
primary antibody (goat anti-ICAM1
[1:200]; rabbit anti-total IKKαβ [1:200];
rabbit anti-pIKKαβ Ser176/180 [1:1000];
mouse anti-total IκBα [1:1000]; mouse
anti-IκBα pSer32/36 [1:1000]; rabbit anti-
NF-κB p65 [1:1000]; rabbit anti-total Akt
[1:1000]; mouse anti-pAkt Ser473 [1:1000];
rabbit anti-total iNOS [1:200]). Mem-
branes were incubated with a secondary
antibody conjugated with horseradish
peroxidase (1:2000) for 30 min at room
temperature and developed with an en-
hanced chemiluminescence (ECL) detec-
tion system. The immunoreactive bands
were visualized by autoradiography and
the densitometric analysis was performed
using Gel Pro Analyzer 4.5, 2000 software
(Media Cybernetics). The membranes
were stripped and incubated with β-actin
monoclonal antibody (1:5000) and subse-
quently with an anti-mouse antibody
(1:10000) to assess gel-loading homogene-
ity. Densitometric analysis of the related
bands is expressed as relative optical
density, corrected for the corresponding
β-actin contents, and normalized using
the related mean value of sham-operated
band.
Serum Nitrite and Nitrate
Nitric oxide synthesis was estimated
through the measurement of serum ni-
trite + nitrate (NOx) in plasma. Briefly,
nitrate was converted to nitrite using ni-
trate reductase in the presence of cofac-
tors. The total nitrite in plasma was as-
sayed by adding Griess reagent (0.05%
[wt/vol] naphthalethylenediamine dihy-
drochloride and 0.5% [wt/vol] sulphanil-
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amide in 2.5% [vol/vol] phosphoric acid)
to each sample and read at 550 nm. NOx
concentrations were calculated by com-
parison with a standard solution of
sodium nitrate prepared in water. Values
are expressed as μmol/L NOx.
Serum Cytokines
Serum cytokines TNF-α, IL-6 and IL-10
were determined using commercial im-
munoassay kits (R&D Systems) accord-
ing to the manufacturer protocol.
Cell Culture
Proximal tubular epithelial cell line
cells from human kidney, HK-2 cells (Eu-
ropean Collection of Cell Cultures, Salis-
bury, UK), were grown in media compris-
ing Dulbecco’s Modified Eagle’s Medium
(DMEM)/Nutrient F-12 Ham (Sigma
Aldrich) supplemented with 10% fetal
calf serum (FCS) and antibiotics
(100 U/mL penicillin G, 100 μg/mL
streptomycin and 0.25 μg/mL ampho-
tericin). Cells were seeded in a 96-well
tissue culture plate and allowed to adhere
for 18 h in an incubator at 37°C (5% CO2
in 95% air). Cells were serum deprived
for 24 h and concomitantly incubated
with IKK16 (10 nmol/L to 100 nmol/L).
Two or 4 h later, IKK16 were removed
and new media (with or without serum)
were added into the wells. Twenty-four
hours later, cell viability was determined
by using the CellTiter 96 nonradioactive
cell proliferation assay kit (Promega) ac-
cording to the manufacturer’s instruction.
Absorbance was measured at 490 nm and
survival was estimated related to control
group (percentage).
Reagents
IKK16 was purchased from Tocris Bio-
science (R&D Systems Europe). Unless
otherwise stated, all compounds used in
this study were purchased from Sigma-
Aldrich. All stock solutions were pre-
pared using nonpyrogenic saline (0.9%
[wt/vol] NaCl (Baxter Healthcare Ltd.).
Ringer lactate was also purchased from
Baxter Healthcare Ltd. The bicinchoninic
acid protein assay kit and SuperBlock
blocking buffer were from Thermo-
Fisher Scientific Inc. Antibodies were
from Cell Signaling Technology Inc.
Data Analysis
All values are expressed as box and
whiskers (minimum to maximum) and
the central line represents the median.
Values on the tables are expressed as
mean ± SD. Statistical analysis was car-
ried out using Graph Prism 5.03 (Graph
Pad Software). Data were assessed by
one-way ANOVA followed by Bonfer-
roni’s post hoc test. A p value of less than
0.05 was considered to be significant.
RESULTS
Effects of IKK16 Treatment on HS
Compared with sham-operated rats,
rats subjected to HS treated with vehicle
exhibited a significant decrease in creati-
nine clearance (Figure 2B), as well as a rise
in serum creatinine (Figure 2A) indicating
the development of renal dysfunction.
Compared with sham-operated rats, HS-
rats treated with vehicle also had elevated
plasma concentrations of AST (Figure 2C)
and ALT (Figure 2D) as well as amylase
(Figure 2E) and lipase (Figure 2F), indicat-
ing the development of liver and pancre-
atic injury, respectively. Compared with
sham-operated rats, HS-rats treated with
vehicle also had elevated plasma concen-
trations of CK (Figure 2G) and lactate (Fig-
ure 2H), indicating the development of
skeletal muscular injury and global tissue
hypoxia, respectively. Treatment of HS-
rats with the inhibitor IKK16 significantly
attenuated the renal dysfunction, liver in-
jury, pancreatic injury and rise in lactate,
but not the skeletal muscular injury associ-
ated with HS (Figure 2). The administra-
tion of IKK16 to sham-operated rats had
no significant effect on any of the bio-
chemical markers evaluated (Figure 2).
Effects of IKK16 Treatment on Lung
Injury
Compared with sham-operated rats,
HS-rats treated with vehicle showed an
increase in MPO-positive cells, a marker
for neutrophils (Figures 3A, C, E), and
CD68-positive cells, a marker for
macrophages (Figures 3F, H, J). Treat-
ment of HS-rats with IKK16 attenuated
the increase in the number of both cell
types in the lung (Figures 3D–E, 3I–J). To
confirm the data obtain by immunohisto-
chemistry, the activity of MPO (indicator
of neutrophil number; Figure 3K) and
NAG (indicator of macrophage number;
Figure 3L) were also determined in lung
tissue. Using this method, we confirmed
that HS leads to an increase in neu-
trophils and macrophages in the lung,
and that this neutrophil/macrophage ac-
cumulation was significantly reduced in
HS-rats treated with IKK16.
We have also investigated the expres-
sion of the intercellular adhesion mole-
cule (ICAM-1), which may be a key
driver for the observed accumulation of
neutrophils in the lung. ICAM-1 expres-
sion increased in lungs of HS-rats com-
pared with sham-operated rats. This in-
crease was attenuated by the treatment
of HS-rats with IKK16 (Figure 3M). No
difference was found in sham animals
treated with IKK16 compared with sham
control animals for any of the parameters
measured (Figure 3).
Effects of IKK16 Treatment on
Inflammatory Cells in Liver and
Kidney
Compared with sham-operated rats,
HS-rats treated with vehicle showed an
increase in MPO-positive cells (indicator
of neutrophil number) in kidney medulla
(Figures 4A, C, E) and liver (Figures 4K,
M, O). No difference among the groups
was observed in the kidney cortex (data
not shown). The treatment of HS-rats
with IKK16 attenuated the increase of
neutrophils in both liver and kidney
(Figures 4D, E, N, O). In contrast, no dif-
ference was found among the groups in
the number of CD68-positive cells (indi-
cator of macrophage number) in these
organs (Figures 4F–J, P–T).
Effects of IKK16 Treatment on Blood
Cells
The following hematological parame-
ters were measured in all animal groups:
Red blood cell count (RBC), hemoglobin
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(HGB), hematocrit (HCT), mean RBC
volume (MCV), mean cell hemoglobin
(MCH), mean cell hemoglobin concentra-
tion (MCHC), red cell distribution width-
SD (RDW-SD), red cell distribution
width–coefficient of variation (RDW-CV),
total reticulocyte count (RET#) and per-
centage (RET%), platelet count (PLT),
platelet distribution width (PDW), mean
platelet volume (MPV), platelet large cell
ratio (P-LCR), plateletcrit (PCT) and
white blood cell counts (WBCs).
Compared with to sham-operated ani-
mals, HS-rats treated with vehicle
showed a slight increase in lymphocyte
cell number, but this rise in lymphocyte
count associated with HS was not af-
fected by IKK16 (Table 1). Neither HS
nor IKK16 had any other significant ef-
fect on any of the other parameters mea-
sured (Tables 1, 2).
Effects of IKK16 Treatment on NF-κB
Pathway
Because the largest (beneficial) effect
of IKK16 was observed in kidney (for
example, reduction in renal dysfunc-
tion) and liver (for example, reduction
in liver injury) (Figure 2), we subse-
quently investigated the effects of
IKK16 on the signaling pathways in-
volved in the activation of NF-κB
and/or cell survival in renal or liver
biopsies obtained from all animal
groups. When compared with sham-
 operated rats, we observed a significant
increase in the phosphorylation of
Ser176/180 on IKKαβ (Figures 5A, D),
Ser32/36 on IκBα (Figures 5B, E) and the
nuclear translocation of the p65 NF-κB
subunit (Figures 5C, F) in the kidney
(Figures 5A–C) and liver (Figures 5D–F)
biopsies obtained from HS-rats treated
with vehicle. Treatment of the HS rats
with IKK16 on resuscitation signifi-
cantly attenuated the phosphorylation
of Ser176/180 on IKKαβ, Ser32/36 on IκBα
and the subsequent translocation of the
p65 NF-κB subunit to the nucleus in
both kidney and liver (Figure 5).
Effects of IKK16 Treatment on iNOS
Expression and NO Production
Induced by HS
Compared with sham-operated rats,
kidneys and livers from rats submitted to
HS (treated with vehicle) exhibited a sig-
nificant increase on iNOS expression
(Figure 6A and B, respectively) and con-
sequently an increase in NOx and, hence,
NO formation (Figure 6C). Interestingly,
treatment of HS-rats with IKK16 at the
onset of resuscitation significantly atten-
uated both iNOS expression in kidney
(Figure 6A) and liver (Figure 6B) as well
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Figure 2. IKK16 protects against multiple organ failure and dysfunction. Rats were sub-
jected to HS and received IKK16 (1 mg/kg; i.v.) or vehicle (Veh) (10% DMSO) at resuscita-
tion. Four hours later, blood was obtained and serum creatinine (A), estimated creatinine
clearance (B), serum AST (C), serum ALT (D), amylase (E), lipase (F), CK (G) and lactate (H)
were determined. Sham animals were used as control. Data are presented as box and
whiskers (minimum to maximum) and the central line represents the median (n = 8–11 ani-
mals per group). *p < 0.05 versus sham group and #p < 0.05 versus HS group.
as the associated rise in serum NOx lev-
els (Figure 6C).
Effects of IKK16 Treatment on Systemic
Cytokines Levels
When compared with sham-operated
animals, the proinflammatory cytokines
TNF-α (Figure 7A) and IL-6 (Figure 7B)
and the antiinflammatory cytokine IL-10
(Figure 7C) were significantly increased
in the serum of HS-rats treated with ve-
hicle. The administration of IKK16 signif-
icantly reduced serum TNF-α, IL-6 and
IL-10 (Figure 7) in serum of HS-rats.
Effects of IKK16 Treatment on Akt
Survival Pathway
To gain a better insight into the poten-
tial mechanisms involved in the beneficial
effects of IKK16, we investigated the ef-
fects of IKK16 on the Akt-survival path-
way, which is known to confer tissue pro-
tection (12,13). In HS-rats, HS did not sig-
nificantly affect the degree of phosphory-
lation of Akt in either kidney or liver
compared with sham-operated rats (Fig-
ures 8A, B). Surprisingly, we discovered,
however, that the degree of Akt phospho-
rylation in tissue biopsies of kidney (Fig-
ure 8A) and liver (Figure 8B) obtained
from HS-rats that had been treated with
IKK16 was significantly increased. Inter-
estingly, no such effect was observed in
sham-operated rats treated with IKK16.
To gain a better understanding of the
role of the potential effects of IKK16 (and
its mechanism of action) on cell survival,
we investigated the effects of IKK16 on
the cell death (apoptosis) caused by
serum deprivation in a human kidney
(proximal tubule) cell line (HK-2 cells). In
HK-2 cells, serum starvation for 24 h re-
sulted in a significant apoptotic cell death
(Figure 8C). Interestingly, treatment of
these cells with IKK16 (10 nmol/L to 
100 nmol/L) during the first 4 h (of the
24 h observation period) significantly re-
duced the cell apoptosis caused by serum
deprivation (Figure 8C).
DISCUSSION
The main findings of this study are
that a potent inhibitor of IKK (IKK16)
protects rats against the multiple organ
dysfunction/failure and inflammation
(lung, kidney, liver) associated with HS;
inhibits the activation of NF-κB and the
expression of NF-κB-dependent proteins
(including iNOS and the cytokines
TNFα, IL-6 and IL-10, and the adhesion
molecule ICAM-1) caused by HS; and ac-
tivates the Akt survival pathway in ani-
mals subjected to HS. We propose that
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Figure 3. IKK16 attenuates lung injury. Rats were subjected to HS and received IKK16 (1 mg/kg; i.v.) or vehicle (Veh) (10% DMSO) at resusci-
tation and 4 h later lungs were obtained. Sham animals were used as control. The representative images for the immunostaining for MPO
as a neutrophils marker (A–D), CD68 as a macrophage marker (F–I), and the quantitative analysis of the number of cells/mm2 (E and J)
are shown. The scale bar represents 50 μm. The activities of MPO (K) and NAG (L) were also determined in lung tissue. The expression of
ICAM-1 was determined by Western blotting. Densitometric analysis of the related bands is expressed as relative optical density, corrected
for the corresponding β-actin contents, and normalized using the related mean value of sham-operated band (M). Data are presented as
box and whiskers (minimum to maximum) and the central line represents the median (n = 5–6 animals per group). *p < 0.05 versus sham
group and #p < 0.05 versus HS group.
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both the inhibition of NF-κB and the acti-
vation of Akt contribute to the observed
beneficial effects of IKK16 in HS.
HS is associated with a high mortality
rate and MOF is the leading cause of late
mortality and extended intensive care
length of stay (16). MOF involves several
mediators and effector cells, and neu-
trophils play an important role in the
pathogenesis of MOF after trauma/HS
(17). We have shown increased numbers
of neutrophils in the main organs af-
fected by HS (lung, kidney and liver).
The presence of neutrophils is usually as-
sociated with endothelial and epithelial
injury. Neutrophils adhere to vascular
endothelium by binding to ICAM-1 on
endothelial cells and then transmigrate
into end organs, causing direct local cy-
totoxic cellular effects via degranulation
and release of substances such as MPO,
NO, ROS and cytokines (18). Treatment
of HS-rats with IKK16 decreased the
number of neutrophils in lung, kidney
and liver, and this antiinflammatory ef-
fect may have contributed to the benefi-
cial effects of IKK16 in these organs. In
the lung, the increase in the neutrophil
number in HS-rats was associated with
(and probably secondary to) an increase
ICAM-1 expression, which was also at-
tenuated by treatment of HS-rats with
IKK16. ICAM-1 is critical in transendo -
thelial migration of neutrophils into 
multiple organs, including the lungs
(19,20). The expression of ICAM-1 in
lungs is upregulated in inflammation,
and antibodies against ICAM-1 are also
able to reduce the migration of neu-
trophils (21,22).
We have investigated the number of
CD68-positive cells, and hence,
macrophages in lung, kidney and liver of
all animals. HS resulted in a significant in-
crease in the number of macrophages in
the lung (but not in kidney or liver),
which was attenuated by treatment of HS-
rats with IKK16. Indeed, alveolar
macrophages play a role in the patho-
physiology of acute lung injury (and
other lung diseases), because these cells
secrete proinflammatory mediators and
growth factors (23). To confirm that HS in-
deed resulted in an increased macrophage
number in the lung, we also measured the
amount of NAG in the lungs of all ani-
mals. HS resulted in an increase in NAG
in the lung, which was reduced by treat-
ment of HS-rats with IKK16.
The activation of NF-κB results in the
transcription of a number of proinflam-
matory cytokines, chemokines and pro-
teins that are widely implicated in the
pathophysiology of MOF. Thus, it is not
surprising that much attention has fo-
cused on the development of drugs and
tools that are able to target this transcrip-
tion factor (8–11,24). However, the effects
of the inhibition of IKK in the MOF in-
duced by HS have not been investigated.
Thus, the present finding is the first ex-
perimental evidence that the therapeutic
administration of an IKK inhibitor at re-
suscitation attenuates multiple organ
dysfunction/injury associated with HS.
The activation of the IKK complex is de-
fined as the phosphorylation of Ser176
and Ser180 on IKKα and Ser177 and Ser181
on IKKβ, which leads to a conformation
change in the activation loop of the com-
plex, catalytically activating the kinase
domain (25). Activation of the IKK com-
plex also requires IKKγ (NF-κB essential
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Table 1. Effect of hemorrhagic shock and IKK16 treatment on white blood cells.a
Sham + Vehicle Sham + IKK16 HS + Vehicle HS + IKK16
WBC (k/μL) 5.34 ± 0.11 5.10 ± 1.38 7.34 ± 1.55 8.17 ± 1.94
Neutrophils (k/μL) 2.11 ± 1.02 1.86 ± 0.66 1.19 ± 1.26 1.95 ± 2.32
Lymphocytes (k/μL) 2.83 ± 1.02 3.03 ± 1.20 5.58 ± 2.10*b 5.6 ± 1.45*
Monocytes (k/μL) 0.33 ± 0.19 0.28 ± 0.03 0.47 ± 0.21 0.56 ± 0.17
Eosinophils (k/μL) 0.06 ± 0.10 0.02 ± 0.02 0.04 ± 0.06 0.03 ± 0.02
Basophils (k/μL) 0.00 ± 0.00 0.01 ± 0.01 0.06 ± 0.06 0.03 ± 0.04
aRats were subjected to HS and received IKK16 (1 mg/kg; i.v.) or vehicle (10% DMSO) at
resuscitation and blood was obtained 4 h later. White blood cells, neutrophils,
lymphocytes, monocytes, eosinophils and basophils were evaluated. Data are presented
as mean ± S.D. (n = 8–11 animals per group).
b*p < 0.05 versus sham group.
Table 2. Effect of hemorrhagic shock and IKK16 treatment on red blood cells and platelet
parameters.a
Sham + Vehicle Sham + IKK16 HS + Vehicle HS + IKK16
RBC (M/μL) 6.29 ± 0.38 6.11 ± 0.56 6.67 ± 0.64 6.61 ± 0.59
HGB (g/L) 13.15 ± 0.59 12.73 ± 0.83 13.89 ± 1.24 13.76 ± 1.38
HCT (%) 40.45 ± 1.64 39.13 ± 3.84 42.88 ± 5.20 42.30 ± 4.45
MCV (fL) 64.43 ± 2.29 64.07 ± 0.64 64.20 ± 3.67 63.98 ± 2.48
MCH (pg) 20.93 ± 0.74 20.90 ± 0.61 20.85 ± 0.81 20.81 ± 0.74
MCHC (g/L) 32.52 ± 0.87 32.60 ± 1.14 32.52 ± 1.16 32.53 ± 0.52
RDW-SD (fL) 32.12 ± 1.51 33.67 ± 1.65 32.68 ± 1.61 32.10 ± 1.64
RDW-CV (%) 16.13 ± 1.09 16.80 ± 1.75 17.45 ± 1.73 16.92 ± 1.29
RET# (k/μL) 462.68 ± 67.6 522.3 ± 147.8 501.7 ± 72.4 479.8 ± 59.4
RET (%) 7.40 ± 1.27 8.49 ± 1.85 7.53 ± 0.90 7.29 ± 0.95
PLT (k/μL) 990.50 ± 177.2 1087.3 ± 49.7 830.9 ± 300.7 954.8 ± 126.6
PDW (fL) 8.38 ± 0.57 8.57 ± 0.47 8.85 ± 0.76 8.60 ± 0.50
MPV (fL) 7.42 ± 0.29 7.43 ± 0.23 7.75 ± 0.52 7.60 ± 0.23
P-LCR (fL) 8.87 ± 1.92 9.03 ± 1.23 11.05 ± 3.24 9.47 ± 1.51
PCT (%) 0.73 ± 0.10 0.80 ± 0.04 0.64 ± 0.22 0.72 ± 0.09
aRats were subjected to HS and received IKK16 (1 mg/kg; i.v.) or vehicle (10% DMSO) at
the resuscitation and blood was obtained 4 h later. Data are presented as mean ± S.D.
(n = 8–11 animals per group).
modulator [NEMO]), which functions as
a chaperone protein that brings the IKK
complex to upstream kinases, leading to
IKK phosphorylation and activation (26).
HS resulted in the phosphorylation of
Ser176/180 on IKKαβ, indicating IKK acti-
vation, which in turn caused the phos-
phorylation of Ser32/36 on IκBα and con-
sequently promoted p65 NF-κB subunit
translocation to the nucleus. Treatment of
HS-animals on resuscitation with IKK16
decreased the phosphorylation of IKKαβ
and, hence, the activation of IKK and ul-
timately NF-κB.
It is well documented that NF-κB regu-
lates iNOS expression, and iNOS-derived
NO is involved on the pathogenesis of
organ injury in HS and septic shock
(27–30). In addition to contributing to
organ injury and vascular decompensa-
tion in HS (27), NO can react with super-
oxide and produce peroxynitrite, which
causes cellular damage and subsequent
tissue injury (31). We showed that HS
caused an upregulation of iNOS expres-
sion in kidney and liver, as well as an in-
crease in systemic NOx levels. Most no-
tably, the inhibition of IKK on
resuscitation attenuated iNOS expression
and NOx production. The reduction of
the iNOS/NO pathway may contribute
to the organ protection afforded by
IKK16, because several strategies which
reduce an excessive formation of NO
also reduce organ injury (32–35).
The proinflammatory cytokines TNF-α
and IL-6 are important mediators of alter-
ations associated with organ dysfunction
and even lethality following hemorrhage
and resuscitation (3,15,36,37). The use of
monoclonal antibodies against TNF-α at-
tenuated the cardiovascular conse-
quences and improved the survival rate
in HS (36), and a monoclonal antibody
against IL-6 reduced organ dysfunction
and inflammation in HS (37). Our results
are in line with these studies, because we
also report an association between high
levels of TNF-α and IL-6 and the devel-
opment of organ injury and dysfunction.
We thus believe that the beneficial effects
of IKK16 on organ failure and dysfunc-
tion followed by HS may, in part, be due
to the reduction of the formation of these
proinflammatory cytokines secondary to
the inhibition of NF-κB.
Inhibitors of the NF-κB pathway may
also prolong the inflammatory response
by preventing (or slowing down) the res-
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Figure 5. IKK16 attenuates the phosphorylation of IKKαβ, IκBα and the nuclear translocation
of the p65 NF-κB subunit. Rats were subjected to HS and received IKK16 (1 mg/kg; i.v.) or ve-
hicle (Veh) (10% DMSO) at resuscitation and 4 h later the phosphorylation of IKKαβ on
Ser176/180 (A and D), IκBα on Ser32/36 (B and E) and the nuclear translocation of the p65 NF-κB
subunit (C and F) on the kidney (A–C) and liver (D–F) were determined by Western blotting.
Sham animals were used as control. Densitometric analysis of the related bands is expressed
as relative optical density (O.D.), corrected for the corresponding β-actin contents, and nor-
malized using the related mean value of sham-operated band. Data are presented as box
and whiskers (minimum to maximum) and the central line represents the median (n = 3–4
animals per group). *p < 0.05 versus sham group and #p < 0.05 versus HS group.
olution of inflammation (38). Indeed, the
fact that inhibitors of NF-κB not only re-
duce proinflammatory mediators, but
also prevent the formation of proteins
which play a key role in the resolution of
inflammation may well be a concern, as
most of these mediators are produced
and released at the same time in inflam-
mation, sepsis and septic shock (39–42).
Thus, we have also evaluated the effects
of IKK16 on the formation of IL-10, a
well-known antiinflammatory cytokine.
We have observed an increase on IL-10
concentration in HS-rats and a reduction
of this cytokine in rats treated with
IKK16. Although enhanced levels of IL-
10 are associated with a better outcome
in some diseases associated with inflam-
mation (43–45), the upregulation of IL-10
has also been associated with immuno-
suppression after sepsis (46) and trauma-
hemorrhage (47,48), resulting in delayed
clinical recovery in trauma patients (39)
and aggravation of lung injury second-
ary to posttraumatic pneumonia (49).
Thus, we believe that the reduction in IL-
10 production may, on balance, con-
tribute to the beneficial effects of IKK16
in trauma/hemorrhage.
To our surprise, we discovered that the
treatment of HS-rats with IKK16 in-
creased the phosphorylation and, hence,
the activation of the kinase Akt. The ki-
nase Akt is a member of the phospho-
inositide 3-kinase signal transduction en-
zyme family, activation of which plays a
pivotal role on the protection of several
organs against ischemia-reperfusion in-
jury (50) and sepsis (12). It is known that
NF-κB is upstream of the activation of
Akt (51), although the functional link be-
tween Akt and the NF-κB pathway is still
controversial. For instance, the activation
of NF-κB by bacterial proteins has been
reported to involve Akt activation (52).
However, other studies have shown that
Akt negatively regulates p65 transactiva-
tion induced by activation of receptors
that recognize either extracellular or in-
tracellular bacterial products (53,54). In
addition, the activation of Akt by IKK16
has been recently reported in sepsis (12)
and lung injury (13). Overall, these data
suggest a complex cross-talk between the
Akt and NF-κB signaling pathways,
which still warrants further investigation.
Moreover, we report here that IKK16
attenuates the severe renal dysfunction
caused by HS, which is frequently associ-
ated with apoptosis or necrosis of proxi-
mal tubule cells (55–57). As the activation
of Akt is also implicated in cell survival
(58–60), we hypothesized that activation
of Akt induced by IKK16 may enhance
cell survival. Thus, we investigated the
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Figure 7. IKK16 attenuates serum inflam-
matory cytokines. Rats were subjected to
HS and received IKK16 (1 mg/kg; i.v.) or
vehicle (Veh) (10% DMSO) at resuscitation
and 4 h later serum concentrations of 
TNF-α (A), IL-6 (B) and IL-10 (C) were deter-
mined. Sham animals were used as con-
trol. Data are presented as box and
whiskers (minimum to maximum) and the
central line represents the median (n = 7–9
animals per group). *p < 0.05 versus sham
group and #p < 0.05 versus HS group; n.d.:
not determined.
Figure 6. IKK16 attenuates the expression of
inducible isoform of nitric oxide synthase
(iNOS) and the serum nitrite + nitrate (NOx).
Rats were subjected to HS and received
IKK16 (1 mg/kg; i.v.) or vehicle (Veh) (Veh)
(10% DMSO) at resuscitation and 4 h later
the iNOS expression in the kidney (A) and
liver (B) was determined by Western blotting
and serum NOx (C) was determined
through Griess reaction. Sham animals were
used as control. Protein expression is mea-
sured as relative optical density (O.D.), cor-
rected for the corresponding β-actin con-
tents and normalized using the related
mean value of sham-operated band. Data
are presented as box and whiskers (mini-
mum to maximum) and the central line rep-
resents the median (A, B: n = 3–4 animals per
group; C: n = 8–9 per group). *p < 0.05 versus
sham group and #p < 0.05 versus HS group.
effect of IKK16 on the survival of human
proximal tubular cells subjected to serum
deprivation. Most notably, concentrations
of IKK16 as low as 10 nmol/L attenuated
the death of proximal tubule cells caused
by serum deprivation. Indeed, this is the
first study that demonstrates that IKK16
protects proximal tubule cells (and in-
deed any other cell line) against cell
death in vitro. Clearly, the death of proxi-
mal tubule cells in response to serum
deprivation is not due to excessive in-
flammation and, hence, the observed
beneficial effects of IKK16 are not related
to its antiinflammatory effects. Thus, we
speculate that activation of Akt by IKK16
improves cell survival (at least of proxi-
mal tubule cells) and may contribute to
its ability to reduce organ injury and dys-
function induced by HS.
Our experimental study of HS has sev-
eral limitations that need to be consid-
ered. The model used here is a very
acute rodent model of severe HS, which
leads to MOF and systemic inflammation
within a few hours of the onset of resus-
citation. Although effective in this acute
setting, we cannot conclude that IKK in-
hibition may be of benefit in other mod-
els of HS (possibly conducted in larger
animals), in which the animals are resus-
citated and followed up for longer peri-
ods after the initial insult. Due to the
short follow-up time, we were unable to
evaluate the effects of IKK16 on long-
term mortality. In our experimental
model, we use heparin to prevent the
formation of clots in our lines. Heparin is
not only an anticoagulant, it also has
many potentially beneficial effects (61),
although these were clearly not sufficient
to prevent the development of organ in-
jury/dysfunction in the model of HS
used here.
CONCLUSION
In conclusion, our data show for the
first time that the potent IKK inhibitor
IKK16 attenuates the organ injury/
 dysfunction associated with HS. This ef-
fect is likely to be due to the prevention
of excessive inflammation (measured as
increase of neutrophil number [lung/
kidney/ liver], increase in macrophage
number [lung], increased expression of
ICAM-1 [lung] and iNOS [lung/kidney/
liver], and enhanced serum concentra-
tion of TNF-α, IL-6, IL-10 and NOx) and
also due to increased activation of the
Akt-survival pathway. Thus, the inhibi-
tion of IKK complex prior to or during
resuscitation represents a novel strategy
for the prevention of organ injury and
dysfunction induced by HS.
ACKNOWLEDGMENTS
R Sordi is supported by the program
Science without Borders, CAPES Foun-
dation, Ministry of Education of Brazil,
Brasilia/DF, Brazil; NSA Patel is, in part,
supported by the Bart’s and The London
Charity (753/1722). The research leading
to these results has received funding
from the People Programme (Marie
Curie Actions) of the European Union′s
Seventh Framework Programme
(FP7/2007-2013) under REA grant agree-
ment n° 608765, from the William Har-
vey Research Foundation and University
of Turin (Ricerca Locale ex-60%). This
work contributes to the Organ Protec-
tion research theme of the Barts Centre
for Trauma Sciences, supported by the
Barts and The London Charity (Award
753/1722) and forms part of the research
themes contributing to the translational
research portfolio of Barts and the Lon-
don Cardiovascular Biomedical Research
Unit, which is supported and funded by
the National Institute of Health Re-
search. The funders had no role in study
R E S E A R C H  A R T I C L E
M O L  M E D  2 1 : 5 6 3 - 5 7 5 ,  2 0 1 5  |  S O R D I  E T  A L .  |  5 7 3
Figure 8. IKK16 increases survival. Rats were
subjected to HS and received IKK16 
(1 mg/kg; i.v.) or vehicle (Veh) (10% DMSO)
at resuscitation and 4 h later the phospho-
rylation of Ser473 and the total Akt on the
kidney (A) and liver (B) were determined
by Western blotting. Sham animals were
used as control. Densitometric analysis of
the related bands is expressed as relative
optical density, corrected for the corre-
sponding β-actin contents, and normal-
ized using the related mean value of
sham-operated band. Data are presented
as box and whiskers (minimum to maxi-
mum) and the central line represents the
median (n = 3–4 animals per group). *p <
0.05 versus sham group and #p < 0.05 ver-
sus HS group. 
Continued in the next column
Figure 8. Continued. (C) HK-2 cells were
serum deprived for 24 h and concomitantly
incubated with indicates concentrations of
IKK16 for the first 4 h. Cell viability was de-
termined by methylthiazoletetrazolium
assay and the absor bance was measured
at 490 nm. Data are presented as box and
whiskers (minimum to maximum) and the
central line represents the median of the
percentage of survival cells related to
complete growth medium (DMEN) control
group. *p < 0.05 versus DMEN group and 
#p < 0.05 versus serum-deprived group.
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